Search Results for: 19

— Steady Progress in All Programs; Two Phase 2 Clinical Trials to Start in 2015 — — Conference Call Today, March 16, 2015, at 8:30 a.m. (ET) — ROCKVILLE, Md., March 16, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting […]

ROCKVILLE, Md., March 11, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that preclinical results supporting the development of SYN-004, the Company’s candidate therapy designed to degrade intravenous (IV) antibiotics within the gastrointestinal (GI) tract and

— Conference Call Scheduled for Monday, March 16, 2015, at 8:30 a.m. EDT — ROCKVILLE, Md., March 9, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, announced today that the Company intends to release its financial results for the

ROCKVILLE, Md., March 3, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, announced today that Jeffrey Riley, Chief Executive Officer, is scheduled to present at the 27th Annual ROTH Conference being held on March 8-11, 2015 at the

ROCKVILLE, Md., March 2, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that preclinical results supporting the development of SYN-005 for the treatment of Pertussis will be highlighted at ECCMID 2015 (European Congress of Clinical Microbiology

ROCKVILLE, Md., Feb. 17, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that preclinical results supporting the development of SYN-010, the Company’s candidate therapy to reduce the impact of methane producing organisms on constipation-predominant irritable

— First-in-Class Drug Candidate to Prevent C. difficile to Begin Phase 2 Testing in 1st Quarter 2015 — ROCKVILLE, Md., Feb. 10, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced positive topline safety and tolerability results

— CEO to Participate on “Trust Your Gut” – Therapeutic Opportunities from the Microbiome Panel — — Company Voted “Most Distinguished Public Company” as part of the Buzz of BIO Contest — ROCKVILLE, Md., Feb. 3, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with

ROCKVILLE, Md., Jan. 7, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, announced today that Jeffrey Riley, CEO, is scheduled to present at the Biotech Showcase™ 2015 Conference next week in San Francisco, as follows: Date: Tuesday, January

— On Schedule to Release Topline Data from Phase 1b Clinical Trial and to Start Phase 2 Clinical Trial of SYN-004 in 1Q 2015 — ROCKVILLE, Md., Dec. 30, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today